May 25, 2017Akcea Announces Publication in The New England Journal of Medicine of Data with AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects
May 15, 2017Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Newly Published Data Characterizes the Burden of Disease in Patients with Familial Chylomicronemia Syndrome
Ionis Pharmaceuticals’ CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award from the American Chemical Society
Ionis Pharmaceuticals Publishes Papers on the Analysis of an Integrated Safety Database and Mechanisms of Antisense Oligonucleotides
Recently Published Preclinical Data Show Reduction of Tau Improves Tauopathy Phenotypes in Mice
We have numerous ongoing clinical trials designed to evaluate our drugs in a variety of health conditions. More »
No upcoming events at this time...